{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T01:17:39Z","timestamp":1786151859628,"version":"3.56.0"},"reference-count":40,"publisher":"Massachusetts Medical Society","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"DOI":"10.1056\/nejmoa2601283","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T12:45:17Z","timestamp":1779713117000},"source":"Crossref","is-referenced-by-count":15,"title":["In Vivo Base Editing of\n                    <i>PCSK9<\/i>\n                    with VERVE-102 for Hypercholesterolemia"],"prefix":"10.1056","author":[{"given":"Scott B.","family":"Vafai","sequence":"first","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"T\u00e4ubel","sequence":"additional","affiliation":[{"name":"Richmond Pharmacology, London"},{"name":"St. George\u2019s University of London, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ashdown","sequence":"additional","affiliation":[{"name":"Richmond Pharmacology, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyaz S.","family":"Patel","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London, London"},{"name":"Barts Health NHS Trust, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Diamondali","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimini","family":"Cegla","sequence":"additional","affiliation":[{"name":"Imperial College London, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handrean","family":"Soran","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research\u2013Wellcome Trust Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Bashir","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research\u2013Wellcome Trust Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6830-3532","authenticated-orcid":false,"given":"Alexander","family":"Abitbol","sequence":"additional","affiliation":[{"name":"LMC Diabetes and Endocrinology, Toronto"},{"name":"Centricity Research, Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal"},{"name":"ECOGENE-21 Clinical Research Center, Chicoutimi, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Lauzi\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal"},{"name":"ECOGENE-21 Clinical Research Center, Chicoutimi, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3686-3807","authenticated-orcid":false,"given":"Liam R.","family":"Brunham","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada"},{"name":"Healthy Heart Program Prevention Clinic, St. Paul\u2019s Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7971-4628","authenticated-orcid":false,"given":"David E.","family":"Newby","sequence":"additional","affiliation":[{"name":"British Heart Foundation Centre for Research Excellence, University of Edinburgh, Edinburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Victorian Heart Institute, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-6480","authenticated-orcid":false,"given":"Russell S.","family":"Scott","sequence":"additional","affiliation":[{"name":"New Zealand Clinical Research, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Kerr","sequence":"additional","affiliation":[{"name":"New Zealand Clinical Research, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[{"name":"Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al, Montreal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lunken","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8221-6547","authenticated-orcid":false,"given":"Steve E.","family":"Humphries","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Karsten","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D.","family":"Tyler","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidal","family":"Huniti","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6441-5860","authenticated-orcid":false,"given":"Patrick A.","family":"Flight","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsey L.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Falzone","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Biedenkapp","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Lister","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie E.","family":"Stolz","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit V.","family":"Khera","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekar","family":"Kathiresan","sequence":"additional","affiliation":[{"name":"Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1509"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/507488"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag148"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514428"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701131"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706728"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.09.017"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"issue":"17","key":"e_1_3_5_14_2","first-page":"e1154","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"153","author":"Blumenthal RS","year":"2026","unstructured":"Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2026;153(17):e1154-e1276.41824552","journal-title":"Circulation"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz962"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1107913"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2013.03.001"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005404"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvz079"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.12.029"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.04.045"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025813"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03534-y"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0491-6"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37465-1"},{"key":"e_1_3_5_28_2","unstructured":"Verve Therapeutics announces updates on its PCSK9 Program. News release of Verve Therapeutics Boston MA April 2 2024 (https:\/\/www.vervetx.com\/sites\/default\/files\/2025-07\/newsarticle-asset-auto-20240402-8406.pdf)."},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309149"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405734"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2412309"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510209"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511778"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04254-4"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22354"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913805"},{"key":"e_1_3_5_37_2","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.","volume":"36","author":"Kastelein JJP","year":"2015","unstructured":"Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015;36:2996-3003.26330422","journal-title":"Eur Heart J"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61399-4"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.20620"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.05.044"},{"key":"e_1_3_5_41_2","unstructured":"Intellia Therapeutics presents positive longer-term phase 1 data of nexiguran ziclumeran (nex-z) in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy. News release of Intellia Therapeutics Cambridge MA November 10 2025 (https:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/intellia-therapeutics-presents-positive-longer-term-phase-1-data)."}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2601283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:28:12Z","timestamp":1780072092000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2601283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":40,"alternative-id":["10.1056\/NEJMoa2601283"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2601283","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"NEJMoa2601283"}}